This provides an incentive to develop novel, biologically relevant IDH1-mutant tumor models to further elucidate the significance of the IDH1R132H mutation in glioma biology and assess the therapeutic potential to correct a potentially causative mutation in brain tumors. This evidence concerns the gene IDH1 and brain neoplasm.